MET and carcinoma: Interestingly, the opposite pattern was observed for the MET/ESR2 coexpression in which high coexpression was associated with younger age at diagnosis, increased NPI, advanced stage and grade of carcinoma, hormone receptor-negative status, and non-luminal tumors.